Synergetic benefits of targeting multiple receptors are being evidenced including simultaneous blocking of CD47 and PD-L1 in cancer immune responses and cytokine release55and dual antibody blockade of CD39 and CD73 combined with ICIs and chemotherapies56. This evidence concerns the gene ENTPD1 and cancer.